Demographics (1)
- age_at_surgery - Age at the time of surgery (phv00318290.v1.p1)
Disease Events (19)
- additional_therapy - Whether adjuvant or salvage therapy was given (phv00318307.v1.p1)
- AFFECTION_STATUS - Case control status of the subject for locally advanced or localized prostate cancer (phv00318280.v1.p1)
- grade_group - Grade group (phv00318297.v1.p1)
- HISTOLOGICAL_TYPE - Tissue type of tumor (phv00318312.v1.p1)
- IS_TUMOR - Tumor status (phv00318311.v1.p1)
- nodes_examined - Number of lymph nodes removed at prostatectomy (phv00318300.v1.p1)
- nodes_involved - Number of lymph nodes with prostate cancer (phv00318301.v1.p1)
- pathologic_stage - Pathologic stage (phv00318293.v1.p1)
- primary_Gleason_grade - Primary Gleason grade (phv00318294.v1.p1)
- PRIMARY_METASTATIC_TUMOR - Primary tumor or synchronous lymph node metastasis (phv00318313.v1.p1)
- secondary_Gleason_score - Secondary Gleason grade (phv00318295.v1.p1)
- stage_group - TNM prognostic stage groups AJCC UICC 2017 (phv00318302.v1.p1)
- surgical_margin - Whether the surgical margin was positive or negative (phv00318299.v1.p1)
- tertiary_Gleason_score - Tertiary Gleason grade, if applicable (phv00318296.v1.p1)
- time_to_recurrence - Time to biochemical recurrence (phv00318306.v1.p1)
- TUMOR_GRADE_GROUP - Tumor grade group (phv00318316.v1.p1)
- TUMOR_STAGE - TNM prognostic stage group AJCC UICC 2017 (phv00318315.v1.p1)
- TUMOR_TREATMENT - Type of tumor treatment for buject (phv00318317.v1.p1)
- tumor_volume - Percent of prostate involved with tumor (phv00318298.v1.p1)
Other (24)
- ANALYTE_TYPE - Analyte Type (phv00318310.v1.p1)
- BODY_SITE - Body site where sample was collected (phv00318309.v1.p1)
- CONSENT - Consent group as determined by DAC (phv00318277.v1.p1)
- DISEASE - Specified disease to which data use must be related (phv00318281.v1.p1)
- ethnicity - Self-described ethnicity of subject (phv00318291.v1.p1)
- germline_sample - Source of the germline sample (phv00318303.v1.p1)
- LIMITATION_MODIFIER - Data use limitation modifier (phv00318282.v1.p1)
- lymph_node_regions - Number of regions examined from positive lymph nodes (phv00318305.v1.p1)
- PRIMARY_TUMOR_LOCATION - Primary tumor location (phv00318314.v1.p1)
- prostate_or_SV_regions - Number of tumor regions examined from the prostate or seminal vesicles (phv00318304.v1.p1)
- PSA - Prostate Specific Antigen (PSA) level measured before prostatectomy (phv00318292.v1.p1)
- SAMPLE_ID - De-identified Sample ID (phv00318308.v1.p1)
- SAMPLE_ID - Sample ID (phv00318284.v1.p1)
- SAMPLE_SOURCE - Source repository where samples originate (phv00318285.v1.p1)
- SAMPLE_USE - Sample Use (phv00318287.v1.p1)
- SEQUENCING_CENTER - Name of the center which conducted sequencing (phv00318318.v1.p1)
- SEQUENCING_TYPE - Type of sequencing conducted (phv00318319.v1.p1)
- SOURCE_SAMPLE_ID - Sample ID used in the Source Repository (phv00318286.v1.p1)
- SOURCE_SUBJECT_ID - Subject ID used in the Source Repository (phv00318279.v1.p1)
- stage_category - Category of pathological stage (phv00318289.v1.p1)
- SUBJECT_ID - De-identified Subject ID (phv00318288.v1.p1)
- SUBJECT_ID - Subject ID (phv00318276.v1.p1)
- SUBJECT_ID - Subject ID (phv00318283.v1.p1)
- SUBJECT_SOURCE - Source repository where subjects originate (phv00318278.v1.p1)